EcoDrugPlus

Fms Related Tyrosine Kinase 4

Ensembl ID : ENSPNYG00000000218
Gene Symbol: FLT4
3 Cross references
193 Possible Orthologues:

Folate Hydrolase 1b

Ensembl ID : ENSPNYG00000013767
Gene Symbol: FOLH1B
3 Cross references
339 Possible Orthologues:

Folate Receptor Alpha-Like

Ensembl ID : ENSPNYG00000013297
Gene Symbol: LOC102204051
3 Cross references
436 Possible Orthologues:

Follicle-Stimulating Hormone Receptor-Like

Ensembl ID : ENSPNYG00000003121
Gene Symbol: LOC102197198
3 Cross references
200 Possible Orthologues:

Free Fatty Acid Receptor 2-Like

Ensembl ID : ENSPNYG00000012404
Gene Symbol: LOC102193772
2 Cross references
338 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSPNYG00000017470
Gene Symbol: FRK
3 Cross references
202 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSPNYG00000009271
Gene Symbol: GLA
3 Cross references
196 Possible Orthologues:

Galectin-3-Like

Ensembl ID : ENSPNYG00000021170
Gene Symbol: LOC102214456
3 Cross references
220 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) B Receptor, 2

Ensembl ID : ENSPNYG00000008853
Gene Symbol: GABBR2
1 Cross references
208 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-1-Like

Ensembl ID : ENSPNYG00000013948
Gene Symbol: LOC102212972
3 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Alpha-2-Like

Ensembl ID : ENSPNYG00000000061
Gene Symbol: LOC102211895
2 Cross references
200 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Alpha4 Subunit

Ensembl ID : ENSPNYG00000000060
Gene Symbol: GABRA4
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).